Novel bioequivalence approach for narrow therapeutic index drugs

Narrow therapeutic index drugs are defined as those drugs where small differences in dose or blood concentration may lead to serious therapeutic failures and/or adverse drug reactions that are life‐threatening or result in persistent or significant disability or incapacity. The US Food and Drug Administration proposes that the bioequivalence of narrow therapeutic index drugs be determined using a scaling approach with a four‐way, fully replicated, crossover design study in healthy subjects that permits the simultaneous equivalence comparison of the mean and within‐subject variability of the test and reference products. The proposed bioequivalence limits for narrow therapeutic index drugs of 90.00%–111.11% would be scaled based on the within‐subject variability of the reference product. The proposed study design and data analysis should provide greater assurance of therapeutic equivalence of narrow therapeutic index drug products.

[1]  T. J. Moore,et al.  Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. , 2007, Archives of internal medicine.

[2]  Sachs Rm,et al.  An evaluation of spontaneous adverse drug reaction monitoring systems. , 1986 .

[3]  Lu Jing,et al.  Statistical approaches to establishing bioequivalence , 2004 .

[4]  Donald J. Schuirmann.  A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  Joint Position Statement on the Use and Interchangeability of Thyroxine Products , 2022 .

[6]  K. Midha,et al.  Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeability , 2009, Epilepsia.

[7]  Michael Levin.  Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .

[8]  S. Takemoto,et al.  Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  Sarfaraz K. Niazi.  Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2004, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition.

[10]  Mays Putrus.  Generic Substitution of Narrow Therapeutic Index Drugs , 2007 .

[11]  Lawrence X. Yu,et al.  Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration , 2012, The AAPS Journal.

[12]  R W Coleman,et al.  A Graphic Nomogram for Warfarin Dosage Adjustment , 1999, Pharmacotherapy.

[13]  Sarfaraz Niazi,et al.  Bioavailability and Bioequivalence Studies for Orally Administered Drug Products , 2004 .

[14]  E. Bortnichak,et al.  An evaluation of spontaneous adverse drug reaction monitoring systems. , 1986, The American journal of medicine.

[15]  C. Gaither,et al.  Pharmacists' Individual and Organizational Views on Generic Medications , 2001 .

[16]  G. Barkley,et al.  Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy , 2007, Neurology.